Abeona Therapeutics vs Keros Therapeutics
ABEO and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and KROS compare
Keros Therapeutics is the larger company, worth 1.5 times as much as Abeona Therapeutics ($224M against $149M).
Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −246% compared with −572% at Keros Therapeutics.
Abeona Therapeutics scores higher on the StockData Score (8 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $149M | $224M |
| Share price | $2.60 | $11.31 |
| Change, 1 year | −41.6% | −34.5% |
| Change, 5 years | −85.8% | −79.8% |
| Beta (5Y) | 1.71 | 2.04 |
| Employees | 226 | 78 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.8× (better) | 15.4× |
| P/B | 1.2× | 0.9× (better) |
| FCF yield | −54.8% | −21.6% (better) |
| Fair value | $3.58 | – |
| Margin of safety | 27.4% | – |
| Growth | ||
| Revenue growth (TTM) | – | −93.7% |
| Revenue growth, 5Y average | −10.3% | – |
| Net income growth (TTM) | −210% (better) | −543% |
| EPS growth (TTM) | – | −1287% |
| Profitability | ||
| Gross margin | 67.1% | – |
| Operating margin | −328% (better) | −698% |
| Net margin | −246% (better) | −572% |
| FCF margin | −319% (better) | −334% |
| Return on equity | −43.1% | −17.2% (better) |
| Return on invested capital | – | −755% |
| Financial health | ||
| Debt / equity | 0.12 (better) | 0.00 |
| Interest coverage | −25.3× | – |
| Current ratio | 6.63 | 21.96 (better) |
| Altman Z-score | −4.80 | 2.67 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 101% |
| Held by insiders | 12.3% | 53.3% |
| Insider net buying, 12 months | −$3.5M | −$453K (better) |
| Short interest, % of float | 33.7% | 11.7% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.